Photo of Tomasz M. Beer, M.D., F.A.C.P.

Tomasz M. Beer M.D., F.A.C.P.

    • Professor of Medicine, Division of Hematology/Medical Oncology School of Medicine
    • Grover C. Bagby Chair of Prostate Cancer Research
    • OHSU Knight Cancer Institute Deputy Director OHSU Knight Cancer Institute School of Medicine
    • Chief Medical Officer, CEDAR OHSU Knight Cancer Institute School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.

Read more

Education

  • M.D., The Johns Hopkins University, Baltimore Maryland 1991
  • Residency:

    • Oregon Health & Science University, Portland
  • Fellowship:

    • Hematology and Medical oncology, Oregon Health & Science University, Portland
  • Certifications:

    • Oncology

Memberships and associations

  • American College of Physicians
  • Oregon Medical Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research
  • Southwest Oncology Group
  • American Urological Association

Publications

  • "Implementing a comprehensive translational oncology platform : From molecular testing to actionability." Journal of Translational Medicine  In: , Vol. 16, No. 1, 358, 14.12.2018.
  • "Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy." Nature communications  In: , Vol. 9, No. 1, 4972, 01.12.2018.
  • "Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer." Annals of oncology : official journal of the European Society for Medical Oncology  In: , Vol. 29, No. 11, 01.11.2018, p. 2200-2207.
  • "Erratum : Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer (Cell (2018) 174(3) (758–769.e9), (S0092867418308420) (10.1016/j.cell.2018.06.039))." Cell  In: , Vol. 175, No. 3, 18.10.2018.
  • "Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer : A multi-institutional prospective study." Journal of Clinical Oncology  In: , Vol. 36, No. 24, 20.08.2018, p. 2492-2503.
  • "DNA repair gene alterations and PARP inhibitor response in patients with metastatic castration-resistant prostate cancer." JNCCN Journal of the National Comprehensive Cancer Network  In: , Vol. 16, No. 8, 01.08.2018, p. 933-937.
  • "Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer." Cell  In: , Vol. 174, No. 3, 26.07.2018, p. 758-769.e9.
  • "LSD1 activates a lethal prostate cancer gene network independently of its demethylase function." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 115, No. 18, 01.05.2018, p. E4179-E4188.
  • "Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer : The PREVAIL randomized clinical trial." JAMA oncology  In: , Vol. 4, No. 5, 01.05.2018, p. 694-701.
  • "Recycling Discarded Drugs : Improving Access to Oral Antineoplastic Drugs." Oncologist  In: , 01.01.2018.
  • "The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients : Exploratory analyses of AFFIRM and PREVAIL studies." European Journal of Cancer  In: , Vol. 87, 01.12.2017, p. 21-29.
  • "Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer." Journal of the National Cancer Institute  In: , Vol. 109, No. 12, 01.12.2017.
  • "Management of anticoagulation in patients with prostate cancer receiving enzalutamide." Journal of Oncology Practice  In: , Vol. 13, No. 11, 01.11.2017, p. 720-727.
  • "In reply." JAMA oncology  In: , Vol. 3, No. 11, 01.11.2017, p. 1588-1589.
  • "Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors." Cancer Discovery  In: , Vol. 7, No. 9, 01.09.2017, p. 999-1005.
  • "Management of castration-resistant, taxane-resistant prostate cancer." ONCOLOGY (United States)  In: , Vol. 31, No. 8, 15.08.2017, p. 1-5.
  • "Management of Castration-Resistant, Taxane-Resistant Prostate Cancer." Oncology (Williston Park, N.Y.)  In: , Vol. 31, No. 8, 15.08.2017, p. 633-636.
  • "Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer." European Journal of Cancer  In: , Vol. 81, 01.08.2017, p. 228-236.
  • "Precision, complexity and stigma in advanced prostate cancer terminology : It is time to move away from 'castration-resistant' prostate cancer." Annals of Oncology  In: , Vol. 28, No. 8, mdx312, 01.08.2017, p. 1692-1694.
  • "Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer." Medicine (United States)  In: , Vol. 96, No. 27, e7223, 01.07.2017.
  • "Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer : An in-depth post hoc analysis of EQ-5D data from the PREVAIL trial." Health and Quality of Life Outcomes  In: , Vol. 15, No. 1, 130, 23.06.2017.
  • "Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer : Data from PREVAIL and AFFIRM trials." Prostate Cancer and Prostatic Diseases  In: , Vol. 20, No. 1, 01.03.2017, p. 110-116.
  • "Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer : post hoc analysis of PREVAIL." Prostate Cancer and Prostatic Diseases  In: , 24.01.2017.
  • "Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer." Journal of Clinical Oncology  In: , Vol. 35, No. 1, 01.01.2017, p. 40-47.
  • "Taking Care of Our Friends and Neighbors : DeVita's The Death of Cancer and the Challenge of Letting Go." JAMA oncology  In: , Vol. 3, No. 1, 01.01.2017, p. 16-17.
  • "Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?" JAMA oncology  In: , Vol. 3, No. 1, 01.01.2017, p. 11-12.
  • "Falls and Frailty in Prostate Cancer Survivors : Current, Past, and Never Users of Androgen Deprivation Therapy." Journal of the American Geriatrics Society  In: , 2017.
  • "Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017." European Urology  In: , 2017.
  • "High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer." Clinical Genitourinary Cancer  In: , 2017.
  • "Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY) : A randomised, open-label, international, phase 3 trial." The Lancet Oncology  In: , 2017.

Additional information

Edit profile